PURPOSE The irreversible ErbB family tyrosine kinase inhibitor (TKI) afatinib plus the EGFR
monoclonal antibody cetuximab was previously shown to overcome resistance to EGFR …

Epidermal growth factor receptor (EGFR) gene mutations identify a molecularly defined
subset of non-small cell lung cancer (NSCLC) patients who display an excellent sensitivity to …

Background Alectinib is a second generation of ALK-tyrosine kinase inhibitors (ALK-TKIs),
which has attracted much attention in the treatment of ALK-positive non-small cell lung …

Background Afaitnib has shown anti-tumor activity against metastatic EGFR-mutated NSCLC
after prior failure to first generation EGFR-TKI and chemotherapy. We prospectively …

What is known and objective Targeted small molecule EGFR Tyrosine Kinase Inhibitors
(TKI's) and the Anaplastic Lymphoma Kinase (ALK) inhibitors have been promising tools for …

Abstract Purpose of Review Anaplastic lymphoma kinase (ALK) rearrangements represent a
seldom event in non-small cell lung cancer (NSCLC). Given the oncogene alteration, ALK …

Background Afatinib is approved for first-line treatment of patients with epidermal growth
factor receptor mutation-positive (EGFR m+) non-small-cell lung cancer (NSCLC). Here, we …

Objective In advanced epidermal growth factor receptor (EGFR)-mutant non-small-cell lung
cancer (NSCLC), treatment with afatinib, a second-generation EGFR-tyrosine kinase …

Background It has no standard treatment strategy for patients with extensive stage small cell
lung cancer (SCLC) who experienced progression with three or more lines of chemotherapy …

Abstract Lessons Learned Apatinib has potential as an effective and safe second-line or
higher treatment for patients with chemotherapy-refractory esophageal squamous cell …